RT Journal Article
SR Electronic
T1 Understanding the chronic kidney disease landscape using patient representation learning from electronic health records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.25.22280440
DO 10.1101/2022.10.25.22280440
A1 Kapur, Karen
A1 Freidank, Moritz
A1 Rebhan, Michael
YR 2022
UL http://medrxiv.org/content/early/2022/10/26/2022.10.25.22280440.abstract
AB Understanding various subpopulations in chronic kidney disease can improve patient care and aid in developing treatments targeted to patients’ needs. Due to the general slow disease progression, electronic health records, which comprise a rich source of longitudinal real-world patient-level information, offer an approach for generating insights into disease. Here we apply the open-source ConvAE framework to train an unsupervised deep learning network using a real-world kidney disease cohort consisting of 2.2 million US patients from the OPTUM® EHR database. Numerical patient representations derived from ConvAE are used to derive disease subtypes, inform comorbidities and understand rare disease populations. To identify patients at high risk to develop end-stage kidney disease, we extend a validated algorithm classifying disease severity to hypothesize subpopulations of rapid chronic kidney disease progressors. We demonstrate that using a combination of data-driven methods offers a powerful exploratory approach to understand disease heterogeneity and identify high-risk patients who could be targeted for early therapeutic intervention to prevent end-stage kidney disease.Competing Interest StatementMixed competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: KK, MF and MR were employed by Novartis at the time the submitted work was produced; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used de-identified electronic health record data available from OPTUM. https://www.optum.com/business/life-sciences/real-world-data/ehr-data.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript